Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages Stemming false Single Family Member true Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:A61K31/00

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.20220305026USE OF POLAPREZINC IN PREPARING DRUG FOR TREATING CASTRATION-RESISTANT PROSTATE CANCER
US 29.09.2022
Int.Class A61K 31/555
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
555containing heavy metals, e.g. hemin, hematin, melarsoprol
Appl.No 17829633 Applicant Jiangnan University Inventor Yongquan CHEN

The present disclosure discloses use of polaprezinc (Pola) in preparing a drug for treating castration-resistant prostate cancer (CRPC) and belongs to the technical field of biological medicine. The present disclosure provides a new strategy for preparing the drug for treating the CRPC by combining the Pola with an androgen receptor antagonist for the first time and conducts a multi-angle and multi-level verification research. A drug composition combining the polaprezinc and the androgen receptor antagonist can be used for treating castration-resistant prostate cancer, remarkably improves an effect of enzalutamide in inhibiting the castration-resistant prostate cancer, realizes new use of the old drug, can greatly shorten time from drug discovery to clinical transformation, and has important clinical treatment significance.

2.20220305005METAL CHELATOR COMBINATION THERAPY FOR THE TREATMENT OF CANCER
US 29.09.2022
Int.Class A61K 31/496
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
495having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
Appl.No 17310262 Applicant Board of Regents, The University of Texas System Inventor Maro OHANIAN

Provided are methods for the treatment of cancers including leukemias, that utilize combination therapies. In some embodiments, a metal chelator is administered to a patient in combination with a cancer therapy, zinc, selenium, magnesium, and vitamin C to treat the cancer. In some embodiments, increased efficacy of the cancer therapy can be observed, and/or lower dosages of a chemotherapeutic may be administered to the subject as a result of the combination therapy.

3.20220306646Deuterated Angiotensin-Converting Enzyme-2 (ACE-2) Inhibitors
US 29.09.2022
Int.Class C07D 495/04
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
495Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
02in which the condensed system contains two hetero rings
04Ortho-condensed systems
Appl.No 17215468 Applicant Daljit Singh Dhanoa Inventor Daljit Singh Dhanoa

The present invention is concerned with novel deuterated Angiotensin-Converting Enzyme-2 (ACE-2) inhibitors of general structural formula I, their optically active enantiomers and diastereoisomers, and pharmaceutical salts and compositions thereof, as well as combination therapies which include compounds of the present invention,

embedded image

These compounds have high potency and selectivity for Angiotensin-Converting Enzyme-2 (ACE-2) inhibition, and are useful in the treatment of infectious respiratory diseases including the pandemic disease Covid-19, Severe Acute Respiratory Syndrome (SARS-CoV-2), Severe Acute Respiratory Syndrome (SARS-CoV), and other diseases caused by coronaviruses.

4.WO/2022/200468USE OF PANTETHINE FOR THE TREATMENT OF SARS COV-2 INFECTIONS
WO 29.09.2022
Int.Class A61K 31/16
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
16Amides, e.g. hydroxamic acids
Appl.No PCT/EP2022/057693 Applicant INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) Inventor LAFORGE, Mireille
SARS-CoV and SARS-CoV-2 share similar pathogenic pathways that interact with pathways of cellular cholesterol metabolism. Depletion of cholesterol from cell membranes reduced the infectivity of SARS-CoV by 90%. Several studies reported that pantethine was able to reduce total cholesterol levels and total fatty acids synthesis but its anti-SARS CoV-2 activity has never been investigated. The inventors now demonstrate that pantethine is highly effective in the control of SARS-CoV-2 infections in vitro. In particular, the inventors show that the effect of pathethine on the inhibition of the replication of SARS-CoV-2 is interested at the dose of 100 μM (inhibition is around 76%) and the most effective concentration is 1000 μM (inhibition is around 98%). Pantethine treatments were able to reduce significantly the expression of the viral Spike and Nucleocapsid proteins and the accessory proteins ORF6. Thus the present invention relates to the use of pantethine for the treatment of a SARS CoV-2 infection.
5.WO/2022/200858TARGETING ONCOGENTIC MUTATIONS WITH DUAL-CLEAVING ENDONUCLEASE
WO 29.09.2022
Int.Class C12N 15/113
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
Appl.No PCT/IB2022/000155 Applicant SPECIFIC BIOLOGICS INC. Inventor STEAD, Brent, E.
Provided herein are compositions and methods of using chimeric nucleases comprising an I-TevI nuclease domain and a Cas domain for the targeting of oncogenes.
6.WO/2022/199373QUINAZOLINE COMPOUND AND USE OF PHARMACEUTICAL COMPOSITION
WO 29.09.2022
Int.Class A61K 31/5377
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
535having six-membered rings with at least one nitrogen and at least one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
53751,4-Oxazines, e.g. morpholine
5377not condensed and containing further heterocyclic rings, e.g. timolol
Appl.No PCT/CN2022/079678 Applicant SHANG YINGLI PHARMACEUTICAL CO., LTD Inventor XU, Zusheng
Disclosed are a quinazoline compound and the use of a pharmaceutical composition. The substance X of the present invention is the quinazoline compound, as represented by formula A; a pharmaceutically acceptable salt thereof; and a solvate thereof, or a solvate of the pharmaceutically acceptable salt thereof. The pharmaceutical composition of the present invention comprises the substance X and a pharmaceutical excipient. The substance X or the pharmaceutical composition provided in the present invention has a good treatment effect on B-cell hematologic neoplasms, and especially has a good treatment effect on follicular lymphoma, and has high efficiency and a good degree of safety.
7.WO/2022/200633MICRORNA-27B INHIBITORS
WO 29.09.2022
Int.Class A61K 31/712
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
70Carbohydrates; Sugars; Derivatives thereof
7088Compounds having three or more nucleosides or nucleotides
712Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
Appl.No PCT/EP2022/058142 Applicant NEUMIRNA THERAPEUTICS APS Inventor KAUPPINEN, Markus Sakari
The present invention provides antisense oligonucleotides complementary to miR-27b, capable of potently inhibiting the activity of miR-27b. Such compounds are useful as pharmaceuticals for treatment of diseases in the CNS or in the PNS including neurological diseases.
8.WO/2022/202403ORAL NEISSERIA-MUCOSA-INCREASING AGENT
WO 29.09.2022
Int.Class A61K 33/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
33Medicinal preparations containing inorganic active ingredients
Appl.No PCT/JP2022/010902 Applicant KAO CORPORATION Inventor FUJII, Akihiko
Provided is a material that is useful for increasing the Neisseria mucosa content in the oral cavity. This oral Neisseria-mucosa-increasing agent has, as active ingredients, a nitrate-ion-supplying compound and one or more sugar alcohols selected from erythritol, xylitol, and mannitol.
9.WO/2022/204368BORONIC ACID COMPOUNDS, COMPOSITIONS AND METHODS
WO 29.09.2022
Int.Class A61K 31/407
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
40having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
407condensed with heterocyclic ring systems, e.g. ketorolac, physostigmine
Appl.No PCT/US2022/021686 Applicant TRUSTEES OF TUFTS COLLEGE Inventor BACHOVCHIN, William W.
Compositions and methods that comprise 1) compounds with one or more substituted or unsubstituted boronic acid moieties (boronic acid compounds) and 2) one or more sulfur-containing compounds. Preferred compositions can exhibit reduced degradation over prolonged time storage periods.
10.WO/2022/204473CRYSTALLINE FORM OF A DIHYDROCHLORIDE SALT OF A JAK INHIBITOR COMPOUND
WO 29.09.2022
Int.Class C07D 471/04
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
471Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/-C07D463/251
02in which the condensed system contains two hetero rings
04Ortho-condensed systems
Appl.No PCT/US2022/021876 Applicant THERAVANCE BIOPHARMA R&D IP, LLC Inventor NZEREM, Jerry
Provided herein is a crystalline form of the dihydrochloride salt of 5-ethyl-2-fluoro-4-(3-(5-(1-methylpiperidin-4-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-6-yl)phenol. Also provided herein are pharmaceutical compositions comprising such crystalline form, methods of using such crystalline form to treat respiratory diseases, and processes useful for preparing such crystalline form.